Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Strativa Pharmaceuticals

Division of Endo International PLC
www.strativapharma.com

Latest From Strativa Pharmaceuticals

Deal Terminations Not The End Of The Road For Licensed Drugs

Post-deal termination, approximately 14% of the drugs from those alliances go on to be approved, and of those still in development, nearly two-thirds advance at least one phase. Third in a series of follow-ups to IN VIVO’s 2014 study comparing/contrasting likelihood of approval and up-front payments on alliances, and the outcomes of relevant deals.

BioPharmaceutical Deals

Deals Shaping The Medical Industry, April 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February through March 2014.

BioPharmaceutical Medical Device

Biopharma Dealmaking Quarterly Statistics, Q3 2012

Q3 2012 biopharma financing, at just over $3 billion, showed a 13% increase over Q2. Follow-on public offerings again were the most prevalent financing type, accounting for a third of these dollars. M&A volume was down to just over $7 billion, compared with Q2’s $35.9 billion and only two Q3 transactions topped the billion-dollar mark. Antibody alliances made up just over a quarter of the total $2.2 billion in deal volume, with 19 deals signed in the area.

BioPharmaceutical Deals

Super Generics – The Next Step For Generic Players As Commoditized Drugs Yield Less Margins – DIA India Conference

It takes tremendous efforts but generic companies eye complex drugs for lasting gains, said DIA India speakers.

BioPharmaceutical India
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Endo International PLC
  • Senior Management
  • Contact Info
  • Strativa Pharmaceuticals
    Phone: (201) 802-4206
    300 Tice Blvd.
    Woodcliff, NJ 07677
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register